MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver diseases, today announced that it will report its third quarter 2026 financial results on Thursday, November 12, 2026.
Altimmune management will host a conference call at 8:30 a.m. ET on November 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website.
Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.
About Altimmune
Altimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in the RECLAIM Phase 2 trial in alcohol use disorder (AUD) and is being studied in alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedIn
Follow @AltimmuneInc on
X
Investor Contact:
Luis Sanay, CFA
[email protected]
Media Contact:
Marisa Sharkey
[email protected]
